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Aims The experiments explored for atrial arrhythmogenesis and its possible physiological background in recently devel-
oped hetero-(RyR2
+/S) and homozygotic (RyR2
S/S) RyR2-P2328S murine models for catecholaminergic polymorphic
ventricular tachycardia (VT) for the ﬁrst time. They complement previous clinical and experimental reports describ-
ing increased ventricular arrhythmic tendencies associated with physical activity, stress, or catecholamine infusion,
potentially leading to VT and ventricular ﬁbrillation.
Methods and
results
Atrial arrhythmogenic properties were compared at the whole animal, Langendorff-perfused heart, and single, iso-
lated atrial myocyte levels using electrophysiological and confocal ﬂuorescence microscopy methods. This demon-
strated that: (i) electrocardiographic parameters in intact anaesthetized wild-type (WT), RyR2
+/S and RyR2
S/S mice
were statistically indistinguishable both before and after addition of isoproterenol apart from increases in heart
rates. (ii) Bipolar electrogram and monophasic action potential recordings showed signiﬁcantly higher incidences
of arrhythmogenesis in isolated perfused RyR2
S/S, but not RyR2
+/S, relative to WT hearts during either regular
pacing or programmed electrical stimulation. The addition of isoproterenol increased such incidences in all three
groups. (iii) However, there were no accompanying differences in cardiac anatomy or action potential durations at
90% repolarization and refractory periods. (iv) In contrast, episodes of diastolic Ca
2+ release were observed
under confocal microscopy in isolated ﬂuo-3-loaded RyR2
S/S, but not RyR2
+/S or WT, atrial myocytes. The introduc-
tion of isoproterenol resulted in signiﬁcant diastolic Ca
2+ release in all three groups.
Conclusions These ﬁndings establish acute atrial arrhythmogenic properties in RyR2-P2328S hearts and correlate these with
altered Ca
2+ homeostasis in an absence of repolarization abnormalities for the ﬁrst time.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an
arrhythmogenic cardiac disorder associated with a characteristic
PVT induced by physical activity, stress, or catecholamine infusion,
which can deteriorate into ventricular ﬁbrillation (VF). Patients typi-
cally present with recurrent syncope, seizures, or sudden death
after physical activity or emotional stress.
1
Two major genes have been implicated in CPVT. One is trans-
mitted as an autosomal dominant trait caused by mutations in the
RyR2 gene.
2 More than 70 distinct RyR2 mutations have been
reported.
2–5 The other is a recessive form caused by mutations in
the cardiac-speciﬁc isoform of CASQ2.
6,7 Mutant RyR2
2 and
CASQ2
6 may inﬂuence myocyte Ca
2+ homeostasis resulting in inap-
propriate ‘leakiness’ of RyR2-Ca
2+ release channels, causing increases
in their basal activity, alterations in their phosphorylation status or
* Corresponding author. Tel: +44 1223 333822; fax: +44 1223 333840, Email: clh11@cam.ac.uk
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-
commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of
publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.
For commercial re-use, please contact journals.permissions@oxfordjournals.org.
Cardiovascular Research (2011) 89, 794–804
doi:10.1093/cvr/cvq229defective interactions of RyR2 with other molecules or ions, including
FKBP12.6
8, CASQ2, or Mg
2+, or its abnormal activation by extra- or
intraluminal Ca
2+.
9 Such changes recently have been investigated
using murine CPVT models containing either R4497C
10 or P2328S
modiﬁcations in the RyR2 gene.
11
There are also reports associating clinical atrial as opposed to ven-
tricular arrhythmias with RyR2 mutations. A large in-frame deletion in
the N-terminal region of RyR2 has recently been correlated with pro-
gressive atrial ventricular block, sino-atrial node dysfunction, atrial
ﬁbrillation (AF), and atrial standstill in addition to the typical
CPVT.
12 Supraventricular arrhythmias including isolated atrial
ectopic beats, non-sustained supraventricular tachycardia, and short
runs of AF have been reported during exercise with an onset
pattern similar to that of the ventricular arrhythmias.
1,13,14 So have
episodes of sinus bradycardia.
1,14,15
However, apart from a recent, important report on the
RyR2-R176Q heterozygotic system, there have been few studies of
atrial arrhythmogenesis in genetically modiﬁed RyR2 mouse
models.
16 In addition, all these studies were conﬁned to heterozygo-
tic, omitting homozygotic variants resulting from the genetic modiﬁ-
cations. The present study accordingly explores for such
arrhythmogenic properties and their possible physiological back-
ground in a recently developed RyR2-P2328S murine model for
CPVT
11 for the ﬁrst time, studying both heterozygotic and homozy-
gotic systems. They thus extend previous ﬁndings on ventricular
arrhythmogenic properties in the P2328S system. We evaluated the
presence or absence of anatomical abnormalities, spontaneous and
atrial arrhythmogenicity, and alterations in action potential recovery
in intact anaesthetized animals, isolated perfused hearts, and altered
Ca
2+ homeostasis in atrial myocytes.
2. Methods
2.1 Animals
Heterozygote RyR2
+/S, homozygote RyR2
S/S, and wild-type (WT)
mice (aged 3–6 months) with an inbred 129/Sv genetic background
(Harlan, UK) were generated as described on a previous occasion.
11
They were kept in plastic cages at room temperature in an animal facility,
given free access to sterile rodent chow and water and subjected to 12 h
light/dark cycles. All procedures were performed in institutional premises
approved under the UK Animals (Scientiﬁc Procedures) Act (1986), under
UK Home Ofﬁce project licence no. PPL No. 80/1974, approved by a uni-
versity ethics review board, accordingly also in conformity with the Guide
for the Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996).
2.2 In vivo surface electrocardiographic
recordings
Mice were anaesthetized using avertin (2,2,2-tribromo-ethanol: Sigma,
Poole, Dorset, UK) in a 24 mg/mL solution at 0.10 mL/(10 g body
weight) dosage injected into the left peritoneal cavity 5 min before electri-
cal recording. They were placed on a heating pad with body temperature
monitoring for three-lead electrocardiographic (ECG) measurements
using subcutaneous needle electrodes employing a Powerlab 26T system
(AD Instruments, Hastings, UK). The digital recordings (16 bit, 2 kHz/
channel) were analysed using the Chart v6.0 program (AD Instruments,
Oxfordshire, UK) giving signal-averaged ECGs and ECG parameters in
which corrected, QT was given as QTc ¼ QT/(RR/100)
1/2.
17 This choice
of injected rather than inhalational anaesthesia permitted experiments
using oesophageal-stimulating electrodes. Preliminary experiments on
WT animals also explored ketamine–xylazine anaesthetic (1.8 mL
ketamine hydrochloride at 100 mg/mL, 0.35 mL xylazine hydrochloride at
23.32 mg/mL, and 2.85 mL of sterile phosphate base solution; adminis-
tration at 0.10 mL/(10 g body weight). However, this gave greater brady-
cardic effects (heart rates 260.6+18.6, n ¼ 12 vs. 410.4+14.5 b.p.m.,
n ¼ 19; P , 0.01) in agreement with previous reports.
18 An isoproterenol
stress protocol involved recording the baseline ECG in lead II for 10 min,
followed by intraperitoneal injection of 2.0 mg/kg isoproterenol.
2.3 In vivo stimulation studies
A further series of in vivo experiments then applied programmed stimu-
lation procedures both before and after the application of isoproterenol
during the ECG recordings in the anaesthetized mice. This used an ultra-
miniature octapolar 1.1 F electrophysiological oesophageal catheter that
permitted connections to stimulating leads (EPR-800, Millar Instrument,
Inc., Houston, TX, USA). The stimulation protocols were performed
after 5 min of stable simultaneous recordings of the baseline surface
ECG. The stimulation protocols ﬁrst applied oesophageal pacing at a
100 ms cycle length (CL) for 30 s. Secondly, a burst pacing procedure
involved pacing hearts at a 40 ms CL of 40 ms in bursts of 2 s duration.
This CL was then decreased in successive 2 s bursts in 2 ms decrements
following sets of three cycles until a CL of 20 ms was reached.
2.4 Electrophysiological studies in
Langendorff-perfused hearts
Langendorff-perfused hearts showing clear-cut 1:1 atrioventricular con-
duction during intrinsic activity following cannulation were studied as
described previously
19,20 using Krebs–Henseleit (K–H) solution (in mM:
NaCl 119, NaHCO3 25, KCl 4.0, KH2PO4 1.2, MgCl2 1.0, CaCl2 1.8,
glucose 10, and sodium pyruvate 2.0) maintained at pH 7.4 by bubbling
with 95% O2–5% CO2 (British Oxygen, Manchester, UK) using the fol-
lowing recording methods: (i) bipolar electrogram (BEG) electrodes
with 1 mm interpole spacings were placed on the left atrium and left ven-
tricle. Hearts were initially paced for .5 min at 10 Hz to permit them to
regain a steady state. The resulting electrogram signals were ampliﬁed for
band-pass ﬁltering between 30 Hz and 1 kHz. (ii) Left atrial monophasic
action potentials (MAPs) were recorded with a microMAP electrode
(Linton Instruments, Harvard Apparatus, UK) for band-pass ﬁltering
between 0.5 Hz and 1 kHz. All signals were recorded using an
NL100AK head stage and NL104 ampliﬁer unit, then band-pass ﬁltered
(Neurolog NL 125/6 Filter, Neurolog, Hertfordshire, UK), then digitized
at 5 kHz by a micro 1401plus MKII laboratory interface (Cambridge
Electronic Design, Cambridge, UK) using Spike2 software (Cambridge
Electronic Design), and action potential durations corresponding to the
time at 90% recovery of the MAPs to baseline (APD90) were determined.
Three types of pacing protocols were used. (i) Hearts were studied at
their intrinsic rates in the absence of stimulation. (ii) Regular pacing at
10 Hz used 2 ms square-wave stimuli set at twice the excitation threshold
(Grass S48 stimulator; Grass-Telefactor, Slough, UK). (iii) Programmed
electrical stimulation (PES) began using standard baseline pacing stimuli
at frequencies of 10 Hz for 20 s. Drive trains of eight paced beats (S1)
were each followed by an extra-stimulus (S2) every ninth beat, initially
at an S1S2 interval equal to the pacing interval. Each subsequent cycle
reduced the S1S2 interval by 1 ms until atrial refractoriness was reached.
2.5 Atrial myocyte isolation
Atrial myocyte isolation used methods described previously.
20 Brieﬂy,
hearts were rapidly excised and cannulated in ice-cold K–H solution
before Langendorff perfusion with a succession of buffers (in mmol/L):
NaCl 125; KCl 4.75; MgSO4 1.2; KH2PO4 1.2; HEPES 30; glucose 10;
taurine 50, titrated to pH 7.4 with NaOH to which was added 750 mM
Ca
2+, 5 mM nitrilotriacetic acid, 1 mg/ml collagenase type II (Worthington,
NJ, USA), and 1 mg/mL hyaluronidase, respectively, at a stable temperature
RyR2 and atrial arrhythmia 795of 37 8C. The heart was then removed and the atrial appendages excised
and chopped into pieces in buffer with reduced enzyme. These were incu-
batedfor5–10 minwithgentlemanualagitation.Cellswerethenseparated
from the enzymatic solution by centrifuging at 243 g for 3 min. The isolated
cells were washed using BSA-containing wash buffer, followed after 5 min
by centrifugation at 30 g for 2 min. The cells were resuspended in normal
K–H solution and, after 5 min, centrifuged again at 30 g for 2 min.
The cells were maintained at room temperature for the experiments that
followed and used within 4–6 h.
2.6 Measurements of Ca
21 transients
Cells placed on a Grade 1 circular laminin-coated cover slip (Menzel, Glas-
bearbeitungswerk, Germany) forming the ﬂoor of a 1.5 mL perfusion
chamber were incubated with 5 mM Fluo-3 AM (Molecular Probes,
Leiden, The Netherlands) in K–H buffer (1.2 mM CaCl2) for 10–20 min
in the dark before washout. Cells were scanned using a Leica TCS SP5
confocal scanning laser microscopy system incorporating a Leica 6000
CS inverted microscope with a ×63 water-immersion objective lens
(numerical aperture 1.2; confocal aperture 600 mm; slice thickness
20.5 mm). The Fluo-3 was excited using a 488 nm argon laser, and emis-
sion collected between 505 and 550 nm. Series of 250 frames (128 ×
64 pixels/frame) were collected at 25 ms/frame. Images were analysed
using custom-made software. Fluorescence, corrected for background
signal in regions outside the cells, was measured within deﬁned regions
of interest (ROIs; F) and normalized to resting (F0) values. Peak F/F0
values were calculated through each time series for each myocyte and a
mean peak F/F0 was calculated for that series. Where indicated, cells
were paced at 1 Hz (5 V above threshold of 30–60 V for 2 ms) with
two ﬁeld electrodes. Ca
2+ transients were measured both from ROIs cov-
ering entire cells, as well as localized ROIs.
Myocytes loaded with Fluo-3 AM were selected for the study of spon-
taneous Ca
2+ release events (sparks) on the basis of their clear striation
pattern, contraction on electrical ﬁeld stimulation by 5–15% of their
resting length, and an absence of spontaneous contractions during a pre-
liminary 1 min observation period. Sparks were recorded in the line scan
imaging mode before and after addition of isoproterenol at resting con-
dition along the long axis of the myocyte. Each scan consisted of 512
pixels (¼40 mm) scanned at intervals of 1 ms over 5 s. Regions were
selected for such imaging with the aid of series of preliminary frame
scans obtained at intervals of 25 ms over 5 s from which a presence of
spontaneous Ca
2+ events could be reconstructed. The frequencies (in
s
21)o fC a
2+ sparks were analysed using an in-house custom-made soft-
ware program. All ﬂuorescence studies were performed at room
temperature.
2.7 Statistical analysis
Data are expressed as means+SEM. The numbers, n, denote either
numbers of whole hearts, the number of cells, or peak F/F0 values. Differ-
ent experimental genotype groups were compared using one-way
ANOVA for correlated samples analysis of variance (SPSS software) and
Student’s unpaired t-test as appropriate, with P , 0.05 considered statisti-
cally signiﬁcant. Categorical variables were compared using x
2 and Fisher’s
exact tests, with P , 0.05 considered signiﬁcant. All chemical agents were
purchased from Sigma-Aldrich (Poole, UK) except where otherwise
indicated.
3. Results
3.1 ECG characteristics of anaesthetized
WT, RyR2
1/S, and RyR2
S/S mice
Gross morphological and light microscopic (haematoxylin and
eosin: Supplementary material online, Figure S1A, C, and E; Masson tri-
chrome: Supplementary material online, Figure S1B, D, and F)
examination showed no obvious structural differences and
Figure 1 In vivo ECG records from anaesthetized WT, RyR2
+/S, and RyR2
S/S, before and after addition of isoproterenol. (A and B) WT hearts in
normal sinus rhythm under both conditions. (C) Normal sinus rhythm before and (D) episodes of bigeminy following addition of isoproterenol in
RyR2
+/S. Episodes of (E) bigeminy before and (F) BVT after adding isoproterenol in RyR2
S/S.
Y. Zhang et al. 796indistinguishable heart to body weight ratios between WT (Sup-
plementary material online, Figure S1A and B), RyR2
+/S (Supplementary
material online, Figure S1C and D), and RyR2
S/S (Supplementary
material online, Figure S1E and F) groups. Figure 1 shows typical
ECG records from steadily beating anaesthetized WT (Figure 1A and
B), RyR2
+/S (Figure 1C and D), and RyR2
S/S hearts (Figure 1E and F)
both before (Figure 1A, C, and E) and after addition of isoproterenol
(2.0 mg/kg; Figure 1B, D, and F). Table 1 summarizes ECG parameters
when hearts were in normal sinus rhythm. These were statistically
indistinguishable between all three groups, under both conditions,
apart from increases in heart rates (P , 0.01, 0.01, and 0.05 in WT,
RyR2
+/S, and RyR2
S/S, respectively; n ¼ 8 mice in each group)
produced by isoproterenol. However, there were contrasting atrial
and ventricular arrhythmogenic features. None of the WT studied
(n ¼ 8) showed arrhythmias whether before or after addition of iso-
proterenol (Figure 1A and B). In contrast, VT and VF did occur in the
RyR2
+/S and RyR2
S/S conﬁrming earlier results.
11 Furthermore, of the
RyR2
+/S (n ¼ 8), one heart showed spontaneous bigeminy lasting for
13.2 s before and three showed ventricular arrhythmias after addition
of isoproterenol. All three of the latter showed episodes of bigeminy
lasting 0.4–5.8 s (Figure 1D), two showed multiple episodes of bidirec-
tional VT (BVT) lasting from 0.5 to 2.5 s. Finally, of the eight RyR2
S/S
mice, one showed episodes of spontaneous bigeminy (Figure 1E)
and BVT both before and after addition of isoproterenol (Figure 1F).
In addition, after addition of isoproterenol, all the RyR2
S/S mice
showed multiple ventricular ectopic beats. Four showed episodes of
bigeminy lasting from 0.5 to 7.4 s, ﬁve showed BVT lasting for
0.5–59.4 s, two showed monomorphic VT lasting from 0.8 to
.......................................................................................................................................................................................
Table 1 Comparison of in vivo ECG parameters in anaesthetized WT, RyR2
1/S, and RyR2
S/S, before and after addition of
isoproterenol
Conditions Genotype n Heart rate
(b.p.m.)
PR interval
(ms)
P-wave duration
(ms)
QRS duration
(ms)
QT interval
(ms)
QTc interval
(ms)
Control WT 8 422.4+17.1 45.2+3.6 9.2+0.8 12.6+0.7 38.9+4.5 32.3+3.6
RyR2
+/S 8 391.4+14.8 49.6+3.0 10.3+1.2 12.3+0.9 38.0+2.7 30.6+2.4
RyR2
S/S 8 422.2+28.5 43.7+2.2 9.4+0.8 11.1+0.8 42.8+7.1 34.5+4.7
Isoproterenol WT 8 503.1+26.5** 53.4+6.4 10.0+1.0 14.2+1.0 47.5+4.3 43.3+3.9
RyR2
+/S 8 464.1+17** 57.4+6.3 9.8+1.0 13.4+1.0 40.6+1.8 35.6+1.5
RyR2
S/S 8 513.0+26.1* 49.8+5.7 11.6+2.2 11.3+1.0 43.2+5.1 39.1+3.7
Control vs. isoproterenol addition *P , 0.05, **P , 0.01.
Figure 2 ECG records obtained during oesophageal stimulation. Typical results from (A and B) WT hearts, (C and D) RyR2
+/S, and (E and F) RyR2
S/S
hearts before (A, C, and E), and following (B, D, and F) addition of isoproterenol. The letter ‘p’ indicates P-wave.
RyR2 and atrial arrhythmia 797Figure 4 BEG records obtained from atria and ventricles during programmed electrical stimulation in WT, RyR2
+/S and RyR2
S/S before and after
introduction of isoproterenol. Atrial (a) and ventricular (b) BEG records showing normal (A) non-sustained (B and C) and sustained (D) AT before (A
and C) and after (B and D) introduction of isoproterenol in WT and RyR2
+/S. Episodes of sustained AT occurred in both conditions in RyR2
S/S (E and F).
The short vertical bars below the traces give the timings of the S1, and the long bars the S2 stimuli in the PES sequences.
Figure 3 BEG records from both the atria and ventricles of WT, RyR2
+/S, and RyR2
S/S hearts before and after introduction of isoproterenol. Atrial
(a) and ventricular (b) BEG records showing normal sinus rhythm before (A and C), but episodes of AT after addition of isoproterenol (B and D)i n
intrinsically beating WT (A and B) and RyR2
+/S (C and D). Episodes of AT in intrinsically beating RyR2
S/S (E and F) both before (E) and following addition
of isoproterenol (F). In panel (A), contributions from atrial activation are labelled ‘A’ and those from ventricular activation are labelled ‘V’.
Y. Zhang et al. 79823.0 s, and one showed multiple PVT episodes lasting from 0.5 to
28.7 s. In contrast, none of the WT, RyR2
+/S,o rRyR2
S/S showed
spontaneous atrial tachycardia (AT) and AF whether in the presence
or absence of isoproterenol.
3.2 In vivo stimulation studies
The subsequent experiments then investigated for the presence or
absence of arrhythmic properties during programmed stimulation
of the in vivo preparation. First, oesophageal pacing was applied at a
100 ms CL for 30 s. Five animals were studied in each group. None
of the WT or heterozygotes showed atrial arrhythmia whether
before and after addition of isoproterenol. One RyR2
+/S mouse
showed bigeminy both before and after addition of isoproterenol.
Of the RyR2
S/S, one animal showed ventricular arrhythmias before
addition of isoproterenol and two showed ventricular arrhythmias
after addition of isoproterenol, one of which was a BVT and
the other was bigeminy. However, none of these showed atrial
arrhythmias.
Secondly, burst pacing was applied to three mice from each
group. Hearts initially showing intrinsic activity were paced at a
CL of 40 ms in bursts of 2 s duration. This CL was then decreased
in successive 2 s bursts in 2 ms decrements following sets of three
cycles until a CL of 20 ms was reached. Cardiac electrical activity
was then measured immediately following such stimulation when
hearts were then permitted to resume intrinsic activity for 5 min.
Results were compared in hearts both before and after the
addition of isoproterenol. None of the three WT mice studied
showed either AT and AF whether or not isoproterenol was
present (Figure 2A and B). However, two mice showed isolated
ectopic ventricular beats after burst pacing after addition of
isoproterenol. In contrast, of the three RyR2
+/S mice studied, one
showed atrioventricular block after burst pacing both before and
after addition of isoproterenol. One showed an AT episode follow-
ing burst pacing lasting 1.78 s (Figure 2C) and one animal showed
spontaneous ventricular bigeminy before addition of isoproterenol.
However, there were no atrial arrhythmic episodes after addition
of isoproterenol (Figure 2D). Of the three RyR2
S/S mice studied,
two showed spontaneous bigeminy and sustained BVT (Figure 2E)
before addition of isoproterenol. All three RyR2
S/S mice showed
BVT after burst pacing both before and after addition of
isoproterenol (Figure 2F); this made it difﬁcult to clarify the atrial
phenotype.
3.3 Comparison of atrial
arrhythmogenicity in isolated WT, RyR2
1/S,
and RyR2
S/S hearts
Experiments in isolated Langendorff-perfused hearts then explored
for spontaneous and provoked atrial arrhythmias. A comparison of
simultaneously recorded bipolar atrial and ventricular traces made it
possible to attribute observed arrhythmias to either atrial or ventricu-
lar activity. Of intrinsically beating WT (Figure 3A and B), RyR2
+/S
Figure 5 MAP recordings from RyR2
+/S and RyR2
S/S during PES before and after introduction of isoproterenol. (A) Non-sustained and (B) sustained
tachycardia observed before (A) and after (B) introduction of isoproterenol in RyR2
+/S. Episodes of sustained AT were observed both before (C) and
after (D) introduction of isoproterenol arrhythmias in RyR2
S/S following PES. (E and F) Numbers of episodes sorted by durations of ,1.0, 1.0–5.0, and
.5.0 s before (E) and following (F) addition of isoproterenol. There were larger numbers of arrhythmic episodes of longer duration in the RyR2
S/S
before addition of isoproterenol (E) than the remaining groups. An increased incidence particularly of brief arrhythmic episodes (,1.0 s) occurred in
all experimental groups (F) following addition of isoproterenol.
RyR2 and atrial arrhythmia 799(Figure 3C and D), and RyR2
S/S (Figure 3E and F), before (Figure 3A, C,
and E) and after introduction of isoproterenol (100 nM; Figure 3B, D,
and F), atrial arrhythmias occurred in isoproterenol-treated WT and
RyR2
+/S (Figure 3A–D) and in RyR2
S/S both before and after isoproter-
enol administration (Figure 3E and F). Similar recordings were made
during PES in WT (Figure 4A and B), RyR2
+/S (Figure 4C and D) and
RyR2
S/S (Figure 4E and F) before (Figure 4A, C, and E) and after
(Figure 4B, D, and F) isoproterenol treatment. Figure 4 exempliﬁes
non-sustained (Figure 4C) and sustained (Figure 4D) atrial arrhythmias
from RyR2
+/S and sustained arrhythmias in RyR2
S/S (Figure 4E and F)
hearts. MAP recordings differentiated these phenomena into AT, as
exempliﬁed in an RyR2
+/S heart (Figure 5A and B) or AF, as exempliﬁed
in an RyR2
S/S heart (Figure 5C and D) both before (Figure 5A and C) and
after (Figure 5B and D) addition of isoproterenol.
Table 2 summarizes the incidence of hearts showing atrial arrhyth-
mogenesis (Columns 3 and 7) for which different experimental
groups were tested against each other for signiﬁcance. The remain-
ing columns provide details concerning the number of episodes
observed as well as their durations. This demonstrates that under
conditions of intrinsic pacing, there were no signiﬁcant differences
in the incidence of atrial arrhythmic episodes between groups.
However, during both regular pacing and PES, the RyR2
S/S, but not
the RyR2
+/S, was more arrhythmogenic than WT in the absence
of isoproterenol. In contrast, both the RyR2
+/S and the RyR2
S/S
were more arrhythmogenic than untreated WT in the presence of
isoproterenol.
Figure 5E and F classiﬁes the numbers of such episodes into dur-
ations of ,1.0, 1.0–5.0, and .5.0 s. Results compared before
(Figure 5E) and after (Figure 5F) addition of isoproterenol demonstrate
larger numbers of arrhythmic episodes of greater duration in the
RyR2
S/S than the remaining groups. Isoproterenol increased the inci-
dence of arrhythmic episodes, particularly of brief episodes (,1.0 s)
in all the experimental groups.
3.4 Atrial arrhythmogenesis in isolated
RyR2
1/S and RyR2
S/S hearts takes place in
the absence of alterations in action
potential waveforms and refractory periods
Previous studies have implicated shortenings of the APD90, and of the
atrial effective refractory periods (AERPs) in re-entrant atrial arrhyth-
mogenicity in murine hearts.
21 The AERP in particular appeared
important as the determinant of the time period in which a given
myocardial region is capable of re-excitation in response to a stimulus,
whether appropriate and originating from the sinus node, or abnormal
ectopic or re-entrant activity.
22 In contrast, prolongations in these
parameters conferred protection from such arrhythmic effects in
studies of murine hearts modelling genetic modiﬁcations in the Na
+
channel.
23 In contrast, the atrial arrhythmogenicity associated with
RyR2 modiﬁcation observed here were not accompanied by altera-
tions in either of these parameters, and therefore appear to reﬂect
a contrasting mechanism. Table 3 (Columns 2 and 3) thus demon-
strates statistically indistinguishable APD90 values obtained from
hearts in each of the three groups during regular pacing; Table 3
(Columns 4 and 5) demonstrates statistically identical AERPs, given
by the shortest S1S2 interval that failed to elicit an action potential.
None of these parameters were signiﬁcantly altered by the introduc-
tion of isoproterenol.
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Table 3 Action potential parameters obtained in WT, RyR2
1/S and RyR2
S/S before and after introduction of isoproterenol
Genotype APD90 (ms) AERP (ms)
Control
(mean+ + + + +SEM)(n)
Isoproterenol
(mean+ + + + +SEM)(n)
Control
(mean+ + + + +SEM) (n)
Isoproterenol
(mean+ + + + +SEM) (n)
WT 20.26+1.57 (6) 17.14+0.84 (5) 24.62+1.30 (13) 23.31+1.48 (13)
RyR2
+/S 18.61+1.33 (9) 19.86+0.54 (5) 23.64+1.64 (14) 25.18+2.71 (17)
RyR2
S/S 19.02+1.06 (7) 19.87+1.12 (6) 26.05+1.95 (20) 25.95+0.95 (19)
Figure 6 Ca
2+ transients from regularly stimulated ﬂuo-3-loaded WT, RyR2
+/S, and RyR2
S/S atrial myocytes studied using confocal microscopy
before and after addition of isoproterenol. Left (A, C, and E) and right (B, D, and F) columns illustrate WT (A, B), RyR2
+/S (C and D), and RyR2
S/S
(E and F)C a
2+ transients before (A, C, and E) and following addition of isoproterenol (B, D, and F). Regular Ca
2+ transients without (A) and
showing diastolic Ca
2+ release (B) before (A) and following (B) addition of isoproterenol in WT (A and B). Diastolic Ca
2+ release (C) whose incidence
was increased by isoproterenol (D) in RyR2
+/S. Multiple episodes of diastolic Ca
2+ release (E) accentuated by addition of isoproterenol (F)i nRyR2
S/S.
Markers below the traces indicating timing of the regular stimulation. (G and H) Frequencies of Ca
2+ sparks among the three genotypes; **denote
differences to a signiﬁcance level of P , 0.01 (G), and before and after addition of isoproterenol; }} and ## both denote differences to a signiﬁcance
level of P , 0.01 (H).
RyR2 and atrial arrhythmia 8013.5 Atrial arrhythmogenesis in isolated
RyR2
1/S and RyR2
S/S hearts is associated
with abnormal Ca
21 homeostasis
In contrast, confocal ﬂuorescence microscope studies in ﬂuo-3-
loaded atrial myocytes demonstrated contrasting patterns in Ca
2+
homeostasis between the three groups. Figure 6 shows typical ﬂuor-
escence traces obtained from WT (Figure 6A and B), RyR2
+/S
(Figure 6C and D), and RyR2
S/S (Figure 6E and F) myocytes regularly
ﬁeld-stimulated at 1.0 Hz before (Figure 6A, C, and E) and after intro-
duction of isoproterenol (100 nM; Figure 6B, D, and F). In contrast to
WT and RyR2
+/S, RyR2
S/S myocytes showed a signiﬁcantly greater inci-
dence of evoked Ca
2+ responses that showed episodes of diastolic
Ca
2+ release in the absence of isoproterenol. The introduction of iso-
proterenol resulted in an increase in such incidences in all the groups,
despite an absence of signiﬁcant difference in peak F/F0 values evoked
by the regular stimulation (Table 4). All these ﬁndings are in exact par-
allel with the incidence of atrial arrhythmia displayed in Table 2. Such
diastolic phenomena would be expected to result in a formation of
delayed after-depolarization events resulting from increased electro-
genic Na
+–Ca
2+ exchanger following the consequent elevations in
cytoplasmic Ca
2+. These could potentially alter membrane voltage
to threshold to give rise to extrasystolic triggered activity.
The above ﬁndings correlated with our estimates of spontaneous
Ca
2+ release events obtained in quiescent atrial myocytes. The pres-
ence of these was clearly demonstrable in the preliminary frame scan
images obtained from cells from all three experimental groups both
before and after addition of isoproterenol. Furthermore, analysis of
their frequencies correlated closely with the corresponding arrhyth-
mic tendencies that were observed at the level of whole hearts.
Thus, Figure 5G and H, Supplementary material online, Figure S2, and
Table 5 demonstrate signiﬁcantly higher event frequencies in RyR2
S/S
(P , 0.01) but not RyR2
+/S compared with WT and in RyR2
S/S com-
pared with RyR2
+/S in the absence of isoproterenol. These differences
disappeared following addition of isoproterenol, an effect attributable
to its action in signiﬁcantly (P , 0.01) increasing event frequency in
WT and RyR2
+/S but not RyR2
S/S.
4. Discussion
The present experiments explored for and characterized acute atrial
arrhythmogenic properties in recently developed hetero-(RyR2
+/S)
and homozygotic (RyR2
S/S) RyR2-P2328S murine models for CPVT,
and investigated their physiological background. The RyR2-P2328S
mutation was ﬁrst described in a Finnish family with CPVT.
3,24
However, clinical reports also associate occasional acute atrial
arrhythmias in patients carrying RyR2 mutations.
12,25 Thus, in
reports including a family with RyR2-P2328S, although all carriers
exhibited polymorphic VT and/or VF, three patients also showed
non-sustained AT.
24 The present experiments demonstrated
acute arrhythmogenic properties in structurally normal atria of
RyR2-P2328S hearts. They correlated these with altered Ca
2+ homeo-
stasis in an absence of abnormalities in action potential repolarization
for the ﬁrst time.
First, in intact anaesthetized animals, mutations in RyR2-P2328S
did not alter baseline ECG parameters during normal sinus
rhythm. ECG parameters in WT, RyR2
+/S, and RyR2
S/S hearts
were statistically indistinguishable. None of three groups showed
signiﬁcant differences in RR, P-wave, QRS complex, and QTc inter-
vals whether before and after addition of isoproterenol apart from
increased heart rates. These ﬁndings paralleled previous clinical
................................................................................ ...................................................................................
.......................................................................................................................................................................................
Table 4 Results of confocal ﬂuorescence microscopy of ﬂuo-3-loaded atrial myocytes during regular stimulation
Genotype Control Isoproterenol
Number of
cells (n)
Number
of peaks
Peak
ﬂuorescence
expressed as F/F0
Number of
episodes of
diastolic
release
Number of
cells (n)
Number
of peaks
Peak
ﬂuorescence
expressed as F/F0
Number of
episodes of
diastolic release
WT 9 141 3.06+0.17 11 7 84 3.18+0.42 13***
RyR2
+/S 15 179 3.64+0.25 12 11 132 2.91+0.27 82
###,****
RyR2
S/S 10 115 2.81+0.28 39
###,}}} 14 168 2.94+0.23 224
###,}}},***
Note: vs. control ***P , 0.001; vs. WT
###P , 0.001; vs. RyR2
+/S }}}P , 0.001.
.......................................................................................................................................................................................
Table 5 Frequencies of spontaneous Ca
21 release events in WT, RyR2
1/S, and RyR2
S/S atrial myocytes before and after
addition of isoproterenol
WT (n) RyR2
1/S (n) RyR2
S/S (n)
Before isoproterenol 0.35+0.12 (12) 0.17+0.07 (9) 1.78+0.44
}},## (10)
After isoproterenol 2.00+0.47 (14)** 2.89+0.43** (11) 1.20+0.40 (10)
**P , 0.01 when compared with the corresponding ﬁndings obtained before addition of isoproterenol.
}}P , 0.01 when compared with ﬁndings obtained from WT before addition of isoproterenol.
##P , 0.01 when compared with ﬁndings obtained from RyR2
+/S before addition of isoproterenol.
Y. Zhang et al. 802reports of the family of RyR2-P2328S mutation carriers
24 and other
clinical examples.
15 The latter thus also showed normal RR inter-
vals, atrioventricular conduction, QRS complex morphology,
ST-segment, and T-wave pattern, although QTc intervals of affected
individuals were slightly longer than those of controls.
24 The
present ﬁndings in RyR2-P2328S hearts also agreed with baseline
ECG parameters in the alternative RyR2-R4496C and RyR2-R176Q
mouse models.
10,26
RyR2
+/S and RyR2
S/S but not WT hearts showed episodic spon-
taneous ventricular arrhythmogenesis in both the absence and the
presence of isoproterenol. Such ventricular arrhythmias often took
the form of BVTs in common with clinical ﬁndings, which also
describe exercise-induced supraventricular arrhythmias that
precede, but which are less common than ventricular tachyarrhyth-
mias in CPVT,
1,27,28 making it less likely they are their direct cause.
The present results similarly showed no incidents of spontaneous
supraventricular arrhythmogenesis. The observed disruptions with
the mutant RyR2 described below therefore likely reﬂect acute
atrial arrhythmogenesis rather than representing chronic arrhythmo-
genic changes following electrical remodeling.
29
Secondly, isolated RyR2
S/S hearts showed atrial arrhythmogenicity in
the absence of alterations in action potential waveforms and AERPs.
Thus, BEG and MAP recordings in isolated perfused preparations
demonstrated signiﬁcantly higher arrhythmogenic incidences in
RyR2
S/S, but not RyR2
+/S, relative to WT hearts during both regular
pacing and PES, even before addition of isoproterenol. The addition
of isoproterenol increased such incidences in all three groups.
These ﬁndings were in contrast to the ECG ﬁndings in the intact
mice. There are thus detailed differences between the murine and
the previously described clinical ﬁndings, with the murine homozy-
gote, but not heterozygote, showing an atrial arrhythmic phenotype,
but then, in the absence of catecholaminergic challenge.
Thirdly, APD90 and AERPs were indistinguishable between the
three groups. This contrasts with predictions of a re-entrant
arrhythmogenic substrate resulting from abnormalities in action
potential recovery as has been associated with gain-of-function
KCNQ1 mutations. The latter involves the Kv7.1 a-subunit responsible
for the slow delayed rectiﬁer K
+. It results in a shortened APD90 and
AERP.
30
Finally, studies in regularly stimulated isolated ﬂuo-3-loaded RyR2
S/S,
but not RyR2
+/S or WT, atrial myocytes contrastingly showed epi-
sodes of diastolic Ca
2+ release under confocal microscopy. RyR2
mutation thus alters atrial Ca
2+ homeostasis. The introduction of iso-
proterenol then resulted in signiﬁcant diastolic Ca
2+ release in all
three groups. These ﬁndings directly parallel the corresponding
observations of the presence or absence of increased atrial arrhyth-
mogenesis in the isolated perfused hearts described above. These
ﬁndings thus implicate alterations in Ca
2+ homeostasis in the
observed atrial arrhythmic properties. This could then take place
through ectopic ﬁring that might contribute to triggering of arrhyth-
mia.
31 These ﬁndings additionally directly parallel our earlier reports
which correlated acute atrial arrhythmogenesis in intact WT hearts
with effects of altered Ca
2+ homeostasis in atrial myocytes following
pharmacological manipulation.
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